Literature DB >> 32651110

Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.

Matthew Ho1, Chia Yin Goh1, Ashish Patel1, Susannah Staunton1, Ronan O'Connor1, Marc Godeau1, Giada Bianchi2.   

Abstract

Multiple myeloma (MM) is a cancer of the plasma cells within the bone marrow (BM). Studies have shown that the cellular and noncellular components of the BM milieu, such as cytokines and exosomes, play an integral role in MM pathogenesis and progression by mediating drug resistance and inducing MM proliferation. Moreover, the BM microenvironment of patients with MM facilitates cancer tolerance and immune evasion through the expansion of regulatory immune cells, inhibition of antitumor effector cells, and disruption of the antigen presentation machinery. These are of special relevance, especially in the current era of cancer immunotherapy. An improved understanding of the supportive role of the MM BM microenvironment will allow for the development of future therapies targeting MM in the context of the BM milieu to elicit deeper and more durable responses. In the present review, we have discussed our current understanding of the role of the BM microenvironment in MM progression and resistance to therapy and discuss novel potential approaches to alter its pro-MM function.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chimeric antigen receptor T cells; Cytokines; Exosomes; MM; Monoclonal antibodies

Year:  2020        PMID: 32651110     DOI: 10.1016/j.clml.2020.05.026

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  9 in total

1.  ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

Authors:  Giada Bianchi; Peter G Czarnecki; Matthew Ho; Aldo M Roccaro; Antonio Sacco; Yawara Kawano; Annamaria Gullà; Anil Aktas Samur; Tianzeng Chen; Kenneth Wen; Yu-Tzu Tai; Maria Moscvin; Xinchen Wu; Gulden Camci-Unal; Matteo C Da Vià; Niccolo' Bolli; Tomasz Sewastianik; Ruben D Carrasco; Irene M Ghobrial; Kenneth C Anderson
Journal:  Cancer Discov       Date:  2021-04-10       Impact factor: 39.397

Review 2.  Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Ashish Patel; Chia Yin Goh; Matthew Ho; Maria Moscvin; Li Zhang; Giada Bianchi
Journal:  Leukemia       Date:  2020-10-12       Impact factor: 11.528

3.  Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Authors:  Rikio Suzuki; Yuka Kitamura; Daisuke Ogiya; Yoshiaki Ogawa; Hiroshi Kawada; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2021-11-05       Impact factor: 2.490

Review 4.  The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.

Authors:  Ivana Lagreca; Giovanni Riva; Vincenzo Nasillo; Patrizia Barozzi; Ilaria Castelli; Sabrina Basso; Francesca Bettelli; Davide Giusti; Angela Cuoghi; Paola Bresciani; Andrea Messerotti; Andrea Gilioli; Valeria Pioli; Corrado Colasante; Daniela Vallerini; Ambra Paolini; Monica Maccaferri; Francesca Donatelli; Fabio Forghieri; Monica Morselli; Elisabetta Colaci; Giovanna Leonardi; Roberto Marasca; Leonardo Potenza; Rossella Manfredini; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Mario Luppi
Journal:  Int J Mol Sci       Date:  2022-05-08       Impact factor: 6.208

Review 5.  Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.

Authors:  Leona Yamamoto; Nicola Amodio; Annamaria Gulla; Kenneth Carl Anderson
Journal:  Front Oncol       Date:  2021-01-27       Impact factor: 6.244

6.  Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.

Authors:  Ignacio Isola; Fara Brasó-Maristany; David F Moreno; Mari-Pau Mena; Aina Oliver-Calders; Laia Paré; Luis Gerardo Rodríguez-Lobato; Beatriz Martin-Antonio; María Teresa Cibeira; Joan Bladé; Laura Rosiñol; Aleix Prat; Ester Lozano; Carlos Fernández de Larrea
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

7.  Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.

Authors:  Paola Storti; Valentina Marchica; Rosanna Vescovini; Valentina Franceschi; Luca Russo; Laura Notarfranchi; Vincenzo Raimondi; Denise Toscani; Jessica Burroughs Garcia; Federica Costa; Benedetta Dalla Palma; Nicolas Thomas Iannozzi; Gabriella Sammarelli; Gaetano Donofrio; Nicola Giuliani
Journal:  Oncoimmunology       Date:  2022-09-06       Impact factor: 7.723

Review 8.  Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.

Authors:  Antonio Giovanni Solimando; Eleonora Malerba; Patrizia Leone; Marcella Prete; Carolina Terragna; Michele Cavo; Vito Racanelli
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

9.  ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

Authors:  Giada Bianchi; Peter G Czarnecki; Matthew Ho; Aldo M Roccaro; Antonio Sacco; Yawara Kawano; Annamaria Gullà; Anil Aktas Samur; Tianzeng Chen; Kenneth Wen; Yu-Tzu Tai; Maria Moscvin; Xinchen Wu; Gulden Camci-Unal; Matteo C Da Vià; Niccolo' Bolli; Tomasz Sewastianik; Ruben D Carrasco; Irene M Ghobrial; Kenneth C Anderson
Journal:  Blood Cancer Discov       Date:  2021-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.